Recombinant hepatitis virus vectors
OwnerD. Lorne J. Tyrrell, Sumonta Chaisomchit +1inventors
InventorsD. Lorne J. Tyrrell, Sumonta Chaisomchit, Lung-Ji Chang
Life of this patent
Estimating the term…
Abstract
The present invention relates to recombinant hepatitis viral vectors useful for the expression of functional heterologous gene products in liver cells. It is contemplated that these vectors will find use in anti-viral, anti-tumor and/or gene therapy, particularly for the correction of inherited single-gene defects. These novel recombinant vectors may be used to deliver genes to cells in vivo by a variety of means including infection and direct injection of vector DNA.
Claims25
A recombinant hepatitis B virus genome comprising heterologous gene sequences which express at least one functional heterologous gene product.
A host cell transfected with a recombinant hepatitis B virus genome comprising pol gene sequences, X gene sequences and preS1/preS2/S gene sequences and heterologous gene sequences wherein said host cell expresses at least one functional heterologous gene product.
A method for encapsidating a recombinant hepatitis B virus genome, comprising:
- a) providing:
- i) a recombinant hepatitis B virus genome comprising pol gene sequences, X gene sequences and preS1/preS2/S gene sequences and heterologous gene sequences wherein said recombinant genome is capable of expressing at least one functional heterologous gene product and wherein said recombinant genome lacks the ability to produce at least one viral product required for packaging said recombinant genome;
- ii) at least one plasmid capable of providing in trans hepatitis B virus gene products sufficient to complement said recombinant viral genome lacking the ability to produce at least one viral product required for packaging;
- iii) a liver cell in vitro;
- and
- b) introducing said recombinant hepatitis virus genome and said at least one plasmid into said liver cell under conditions such that said recombinant hepatitis virus genome is encapsidated into viral particles.
Dependencies are inferred from the claim text.